Health Populi
APRIL 24, 2018
Among these people, healthcare trust fell by 20 percentage points between 2017 and 2018, a “crash” (Edelman’s descriptor) from 75 percent to 55%. Biotech is roughly tied for second place with consumer health, dropping also by 7 points. In that context, look at chart #4, “Biotech Seen as the Laboratory vs Pharma.”
Health Populi
MAY 20, 2021
Year-on-year, different spikes and ups-and-downs call out for special mention, such as: Pharma’s 13-point steep dive to 38% between 2017 and 2018, dramatically recovering by 9 points in the last year to 47% [with the wild card here of whether U.S. to approve Medicare’s negotiation of drug prices with pharmaceutical companies].
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Health Global
OCTOBER 11, 2023
The acquisition immediately expands EVERSANA’s European operations and worldwide capabilities to help pharmaceutical, medical device, and emerging biotech companies globally launch products, expand market access, or solve unique geographic and market-specific challenges.
Lloyd Price
NOVEMBER 10, 2018
One of the biggest gambles in biotech history is about to be tested on Wall Street. In its prospectus, Moderna set an initial target of $500 million for the offering, which would make it the largest biotech IPO in history. Unlike a typical biotech going public, Moderna has a pipeline of 21 programs, 10 of which are in human testing.
Society for Participatory Medicine
FEBRUARY 1, 2023
This activity sent pharma and biotech companies scrambling to hire DE&I officers and related patient advocacy, engagement, and experience personnel as they came to terms with this foreign notion of actually collaborating with real, live patients. She is currently contracted by Parexel as their first Patient Ambassador.
Health Populi
MAY 30, 2018
This is important because in 2017, one in four new drugs approved by the FDA were designed to treat a small population, falling. The team analyzed data-sharing guidelines across 230 policy documents published between 1996 and 2017. into the precision medicine category. Note that autonomy and privacy rank with the most mentions.
Lloyd Price
JULY 5, 2018
For many biotech companies, mergers and acquisitions have become a cornerstone in building a robust pipeline that can ensure positive growth for years to come. Although 2017 was slow for M&A activity, analysts have predicted 2018 could be a return to a spending frenzy. 2017 was considered to be a lean year for M&A in biotech.
Expert insights. Personalized for you.
185 
Let's personalize your content